Nuwellis Regains Compliance with Nasdaq Listing Requirements

Core Points - Nuwellis, Inc. has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, allowing its common stock to continue trading on the Nasdaq Capital Market under the symbol "NUWE" [1][2][3] - The company improved its balance sheet by raising $5.1 million in gross proceeds from warrant exercises and a warrant inducement transaction, and it now exceeds the equity requirement of at least $2.5 million [2][3] - A reverse stock split of 1:35 was implemented on June 26, 2024, as part of the company's compliance efforts [3] Company Overview - Nuwellis, Inc. is a medical device company focused on transforming the lives of patients suffering from fluid overload through innovative therapies [4] - The company is commercializing the Aquadex SmartFlow® system, which is designed for ultrafiltration therapy in patients with hypervolemia [5] - The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kg or more, whose fluid overload is unresponsive to medical management [5]